Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Amgen announces deal with Ortho-McNeil-Janssen Pharmaceuticals

Amgen announces deal with Ortho-McNeil-Janssen Pharmaceuticals

4th August 2008

Amgen has licensed a molecule which is used to treat chronic and neuropathic pain to the Johnson & Johnson company, Ortho-McNeil-Janssen Pharmaceuticals (OMJPI).

OMJPI will pay Amgen $50 million (25.3 million pounds) upfront and could end up handing over $385 million more depending upon further success and sales-based milestones and royalties on sales.

The agreement means OMJPI will have global rights to the product, excluding Japan where Amgen already has a licence agreement for the compound.

OMJPI will take control of future development and commercialisation of the compound which is a fully human anti-nerve growth factor antibody.

Amgen’s executive vice president of research and development, Roger Perlmutter, said: “OMJPI’s proven capabilities in developing and marketing pain therapeutics make them an ideal partner to bring this potentially important molecule to patients who suffer chronic pain.”

Before the deal can go ahead it will be subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act.

Amgen discovers, develops, makes and delivers human therapeutics.

It claims to have changed medicine practice around the world by helping millions of people fight against kidney disease, cancer, rheumatoid arthritis and other serious illnesses.

Last month, Amgen announced positive top-line results for its denosumab pivot postmenopausal osteoporosis trial.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.